Floatz logo

Tisagenlecleucel

Diffuse Large B Cell Lymphoma

University of UtahCell therapyPhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
73/ 100

Competitive context

87 Active assets in the Diffuse Large B Cell Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Beth Israel Deaconess Medical Center
Phase 4BBB
Cyclophosphamide
Beth Israel Deaconess Medical Center
Phase 4BBB
Cytosin-Arabinosid
University of California, Davis
Phase 4BB
cc-5013
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 3BB
Ifosfamide
The First Affiliated Hospital with Nanjing Medical University
Phase 4BB

View all 50 →

Same molecule, other indications

Tisagenlecleucel is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
64 / 100
View asset →
Primary Mediastinal Large B Cell LymphomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →